Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 55 Kidney Neoplasms 15 Neoplasms 13 Carcinoma, Non-Small-Cell Lung 10 Neoplasm Metastasis 8 Melanoma 7 Colorectal Neoplasms 7 Carcinoma, Hepatocellular 7 Carcinoma 6 Glioblastoma 5 Lung Neoplasms 4 Uterine Cervical Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Thyroid Neoplasms 2 Stomach Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Liver Neoplasms 2 Kidney Diseases 2 Advanced Solid Tumors 2 cT2a N0NxM0 Renal Tumor 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

Docetaxel 16 Cisplatin 15 Carboplatin 12 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Cetuximab 9 Biopsy 9 pembrolizumab 8 Paclitaxel 8 Immunohistochemistry 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Radiotherapy, Intensity-Modulated 7 Chemotherapy, Adjuvant 7 Specimen Handling 6 Gemcitabine 6 Radiotherapy, Conformal 5 Vorinostat 4 Taxes 4 Radiosurgery 4 Gene Expression Profiling 4 Fluorodeoxyglucose F18 4 Capecitabine 4 Bevacizumab 4 trastuzumab deruxtecan 3 darolutamide 3 Surgical Procedures, Operative 3 Sorafenib 3 Radiation 3 Polymerase Chain Reaction 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02857712 2019-08-30

SGC-AX14

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡